Voyager Therapeutics reports Q4 and full year 2025 financial results

Voyager Therapeutics filed an 8-K on March 9, 2026, to announce its fourth quarter and full year 2025 financial and operating results. This is a standard earnings announcement filing where the company furnishes results via press release rather than incorporating them directly into the 8-K document. The actual financial figures, performance metrics, and corporate updates are contained in the attached press release (Exhibit 99.1).

Retail investors should review the full press release to understand the company's financial performance for 2025, including revenue, expenses, cash position, and any operational milestones achieved during the period. As a clinical-stage biotechnology company, key items to watch include clinical trial progress, partnership developments, and cash runway sufficiency. Investors should monitor subsequent filings, particularly the 10-K annual report, for complete audited financials and management's discussion of business strategy and risks.